Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
P/E Ratio
--
P/B Ratio
1.24
Industry P/E
--
Debt to Equity
0
ROE
-4.2 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-379.65 Mln
EBITDA
$-483.59 Mln
Net Profit
$-616.01 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
VBI Vaccines Inc. New (Canada) (VBIV)
| -96.95 | -71.38 | -97.00 | -98.55 | -94.41 | -74.49 | -60.64 |
|
BSE Sensex*
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
VBI Vaccines Inc. New (Canada) (VBIV)
| -94.97 | -83.33 | -14.91 | 99.28 | -13.75 | -62.33 | 37.74 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company... also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts. Read more
President, CEO & Director
Mr. Jeffery R. Baxter FCMA
President, CEO & Director
Mr. Jeffery R. Baxter FCMA
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of VBI Vaccines Inc New (Canada) (VBIV) stood at $ 153 Mln as on 31-Mar-24
The share price of VBI Vaccines Inc New (Canada) (VBIV) is $0.02 (NASDAQ) as of 06-Sep-2024 09:30 EDT. VBI Vaccines Inc New (Canada) (VBIV) has given a return of -94.41% in the last 3 years.
VBI Vaccines Inc New (Canada) (VBIV) has a market capitalisation of $ 2 Mln as on 06-Sep-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of VBI Vaccines Inc New (Canada) (VBIV) is 1.24 times as on 06-Sep-2024, a 56% discount to its peers’ median range of 2.79 times.
Since, TTM earnings of VBI Vaccines Inc New (Canada) (VBIV) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the VBI Vaccines Inc New (Canada) (VBIV) and enter the required number of quantities and click on buy to purchase the shares of VBI Vaccines Inc New (Canada) (VBIV).
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
The CEO & director of Mr. Jeffery R. Baxter FCMA. is VBI Vaccines Inc New (Canada) (VBIV), and CFO & Sr. VP is Mr. Jeffery R. Baxter FCMA.
There is no promoter pledging in VBI Vaccines Inc New (Canada) (VBIV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| VBI Vaccines Inc. New (Canada) (VBIV) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-423
|
|
Net Margin(%)
|
-2396.33
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of VBI Vaccines Inc New (Canada) (VBIV) was $-45 Mln.
$--
(
